IRIS
CARLO STELLA, CARMELO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.691
AS - Asia 3.774
EU - Europa 1.539
SA - Sud America 994
AF - Africa 271
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 7
Totale 15.286
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.529
SG - Singapore 2.511
BR - Brasile 852
CN - Cina 691
FI - Finlandia 366
IE - Irlanda 251
DE - Germania 215
NG - Nigeria 205
VN - Vietnam 150
FR - Francia 125
IT - Italia 124
HK - Hong Kong 121
GB - Regno Unito 118
CA - Canada 107
NL - Olanda 76
IN - India 46
RU - Federazione Russa 44
SE - Svezia 42
TR - Turchia 42
AR - Argentina 40
MX - Messico 34
EC - Ecuador 32
CZ - Repubblica Ceca 30
BD - Bangladesh 28
IL - Israele 26
IQ - Iraq 25
BE - Belgio 21
ES - Italia 21
ID - Indonesia 20
CL - Cile 19
PL - Polonia 19
JP - Giappone 18
UA - Ucraina 17
ZA - Sudafrica 17
LT - Lituania 16
CO - Colombia 14
AT - Austria 13
UZ - Uzbekistan 13
PY - Paraguay 12
EG - Egitto 11
MA - Marocco 11
SA - Arabia Saudita 11
PK - Pakistan 10
VE - Venezuela 10
KE - Kenya 9
RO - Romania 9
IR - Iran 8
UY - Uruguay 8
A2 - ???statistics.table.value.countryCode.A2??? 7
JO - Giordania 7
AU - Australia 6
KR - Corea 6
NP - Nepal 6
PE - Perù 6
TN - Tunisia 6
DK - Danimarca 5
DO - Repubblica Dominicana 5
JM - Giamaica 5
AM - Armenia 4
AZ - Azerbaigian 4
DZ - Algeria 4
GR - Grecia 4
TT - Trinidad e Tobago 4
AE - Emirati Arabi Uniti 3
CH - Svizzera 3
PH - Filippine 3
SN - Senegal 3
TH - Thailandia 3
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BY - Bielorussia 2
CR - Costa Rica 2
ET - Etiopia 2
GA - Gabon 2
GE - Georgia 2
HN - Honduras 2
HR - Croazia 2
KH - Cambogia 2
KZ - Kazakistan 2
LK - Sri Lanka 2
LV - Lettonia 2
MY - Malesia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
OM - Oman 2
AL - Albania 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CI - Costa d'Avorio 1
EE - Estonia 1
GD - Grenada 1
GT - Guatemala 1
HU - Ungheria 1
KG - Kirghizistan 1
LB - Libano 1
LU - Lussemburgo 1
MD - Moldavia 1
MT - Malta 1
Totale 15.280
Salva come PNG Salva come JPEG
Città #
Wilmington 1.310
Chandler 1.266
Singapore 820
The Dalles 672
Dallas 589
San Mateo 502
Shanghai 475
Helsinki 360
Ann Arbor 332
Ashburn 260
Dublin 250
Leawood 243
Boardman 235
Lawrence 225
Princeton 225
Benin City 205
New York 135
Fairfield 124
Hong Kong 119
Paris 112
Beijing 95
Woodbridge 95
Amsterdam 73
São Paulo 66
Columbus 63
London 63
Toronto 63
Los Angeles 62
Ho Chi Minh City 51
Seattle 50
Milan 35
Santa Clara 33
San Diego 31
Rio de Janeiro 29
Munich 28
Norwalk 27
Falls Church 26
Phoenix 24
Brno 23
Hanoi 23
Montreal 23
Council Bluffs 22
Brussels 21
Belo Horizonte 20
Brasília 19
Brooklyn 19
Naples 19
Warsaw 16
Campinas 15
Kocaeli 15
Curitiba 13
Monmouth Junction 13
Moscow 13
Stockholm 13
Tashkent 13
Guayaquil 12
Gunzenhausen 12
Boston 11
Chicago 11
Houston 11
Nuremberg 11
Tokyo 11
Pune 10
Redmond 10
Vienna 10
Abbiategrasso 9
Ankara 9
Atlanta 9
Johannesburg 9
San Francisco 9
Guarulhos 8
Porto Alegre 8
Quito 8
Amman 7
Dhaka 7
Haiphong 7
Recife 7
Andover 6
Caxias do Sul 6
Charlotte 6
Goiânia 6
Jakarta 6
Joinville 6
Mexico City 6
Montevideo 6
Newark 6
Osasco 6
Poplar 6
Redwood City 6
Riyadh 6
Seoul 6
Sorocaba 6
Taubaté 6
Berlin 5
Biên Hòa 5
Buenos Aires 5
Buffalo 5
Bắc Giang 5
Chennai 5
Clearwater 5
Totale 10.010
Salva come PNG Salva come JPEG
Nome #
Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis 158
Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin’s lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin®) 119
Age- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone (rhGH) 113
ACQUIRED CYCLIC THROMBOCYTOPENIATHROMBOCYTOSIS WITH PERIODIC DEFECT OF PLATELET-FUNCTION 112
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma 112
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K delta/gamma Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study 105
American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma 104
A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments 98
A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogenic stem call transplantation from a HLA identical sibling 98
Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome 96
Limited engraftment capacity of bone marrow-derived mesenchymal cells following T-cell-depleted hematopoietic stem cell transplantation 91
Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma 90
D Quantification of Tumor Vasculature in Lymphoma Xenografts in NOD/SCID Mice Allows to Detect Differences among Vascular-Targeted Therapies 87
A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Circulating Tumor DNA 83
A case of acute myeloid leukemia, with pseudo-Pelger neutrophils 82
[Mesenchymal stem cells: biology and clinical applications] 81
Therapeutic relevance of CD34+ cell dose in blood cell transplantation for cancer therapy 79
A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma 79
Cardioprotection with nebivolol in patients undergoing anthracyclines: a randomized placebo-controlled trial 78
T-lymphocyte function after retroviral-mediated thymidine kinase gene transfer and G418 selection 78
T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes 78
Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis 77
Cell therapy: achievements and perspectives 76
Detection of maternal progenitor cells in human umbilical cord blood by single-colony karyotyping 76
Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin's lymphoma. Assessment of risk of toxicity and secondary cancer induction 76
Computed tomography (CT)-derived radiomic features differentiate prevascular mediastinum masses as thymic neoplasms versus lymphomas 76
Are EBV-related and EBV-unrelated Hodgkin lymphomas different with regard to susceptibility to checkpoint blockade? 75
"Overshoot" phenomenon in circulating granulocytic progenitor cell growth during remission of blast crisis in a case of CML 74
Radioimmunotherapy and secondary leukemia : a case report 74
Expression and activation of SHC/MAP kinase pathway in primary acute myeloid leukemia blasts 74
AUTOLOGOUS TRANSPLANT FOR CHRONIC MYELOGENOUS LEUKEMIA USING MARROW TREATED EX-VIVO WITH MAFOSFAMIDE 73
INVITRO MEGAKARYOCYTOPOIESIS IN PATIENTS WITH HIV-RELATED THROMBOCYTOPENIC PURPURA 73
Amifostine (WR-2721) selective protection against melphalan genotoxicity 72
New reciprocal translocation t(5;10)(q33;q22) associated with atypical chronic myeloid leukemia 71
Primary refractory and early-relapsed Hodgkin's lymphoma : strategies for therapeutic targeting based on the tumour microenvironment 71
Defibrotide in combination with granulocyte colony-stimulating factor significantly enhances the mobilization of primitive and committed peripheral blood progenitor cells in mice 71
AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN ACUTE MYELOGENOUS LEUKEMIA 71
Arachidonic acid induces c-jun gene expression in stromal cells stimulated by interleukin-1 and tumor necrosis factor-a: evidence for a tyrosine-kinase-dependent process 70
Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation 70
EFFECT OF RECOMBINANT GAMMA-INTERFERON ON THE PROLIFERATIVE ACTIVITY OF CULTURED LEUKEMIC-CELLS 69
Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide 69
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia : evidence for premature aging of the myeloid compartment 68
UMBILICAL-CORD BLOOD AS A SOURCE OF HEMATOPOIETIC STEM-CELLS - FROM RESEARCH TO CLINIC 67
Bleomycin genotoxicity and amifostine (WR-2721) cell protection in normal leukocytes vs. K562 tumoral cells 67
Dendritic cell viability is decreased after phagocytosis of apoptotic tumor cells induced by staurosporine or vaccinia virus infection 67
EFFECT OF RECOMBINANT INTERFERON-ALPHA AND INTERFERON-GAMMA ON HUMAN-BONE MARROW DERIVED MEGAKARYOCYTIC PROGENITOR CELLS 66
Detection of minimal residual disease in hematopoietic progenitor cell harvests : lack of predictive value of peripheral blood and bone marrow analysis in mantle cell and indolent lymphoma 66
Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma 65
High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant 65
Specific histone patterns and acetylase/deacetylase activity at the breakpoint-cluster region of the human MLL gene 65
Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells 65
Risk of Cancer in Inflammatory Bowel Diseases: Umbrella Review and Reanalysis of Meta-analyses 64
Vascular amounts and dispersion of caliber-classified vessels as key parameters to quantitate 3D micro-angioarchitectures in multiple myeloma experimental tumors 64
Stem cells and stem cell transplantation 64
Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma 64
B-cell reconstitution recapitulates B-cell lymphopoiesis following haploidentical BM transplantation and post-transplant CY 64
Stem cell manipulation: why and how performing peripheral blood progenitor cell purging 64
ESTABLISHMENT OF 2 EPSTEIN-BARR VIRUS NEGATIVE BURKITT CELL-LINES FROM A PATIENT WITH AIDS AND B-CELL LYMPHOMA 62
BIOLOGICAL ASPECTS AND CLINICAL-APPLICATIONS OF LONG-TERM BONE-MARROW CULTURE - A MEETING REPORT 62
Tumor-derived PGD2 and NKp30 –B7H6 engagement drives an immunosuppressive ILC2-MDSC axis 62
Autophagy as a pathogenic mechanism and drug target in lymphoproliferative disorders 62
CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice 62
T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors. 62
Salvage Therapy for Hodgkin's Lymphoma: A Review of Current Regimens and Outcomes 62
Effect of the protein tyrosine kinase inhibitor genistein on normal and leukaemic haemopoietic progenitor cells 61
INVITRO AND INVIVO EFFECTS OF RECOMBINANT INTERFERON GAMMA ON THE GROWTH OF HEMATOPOIETIC PROGENITOR CELLS FROM PATIENTS WITH MYELODYSPLASTIC SYNDROME 61
Selective expression and constitutive phosphorylation of SHC proteins [corrected] in the CD34+ fraction of chronic myelogenous leukemias 61
Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia 61
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases 61
Antitumor activity of human CD34+ cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand (mTRAIL) 61
Biologic and phenotypic analysis of early hematopoietic progenitor cells in umbilical cord blood 61
NATURAL-KILLER-CELL REGENERATION AFTER TRANSPLANTATION WITH MAFOSFAMIDE PURGED AUTOLOGOUS BONE-MARROW 61
Transforming growth factor beta(3) inhibits chronic myelogenous leukemia hematopoiesis by inducing Fas-independent apoptosis 61
CD34-POSITIVE CELLS - BIOLOGY AND CLINICAL RELEVANCE 60
Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory Hodgkin Lymphoma 60
Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunological responses in indolent B-cell lymphoma patients with relapsed and measurable disease : a pilot study 60
Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma : a single institution experience 60
Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide 60
Genetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin's lymphoma 60
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen) 59
Forced Expression of RDH10 Gene Retards Growth of HepG2 Cells 59
The novel PI3K-ò inhibitor TGR-1202 enhances brentuximab vedotin-induced Hodgkin lymphoma cell death via mitotic arrest. 59
Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma : Final results of a multicenter phase II study 59
Phase II study of sorafenib in patients with relapsed or refractory lymphoma 59
BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts 59
Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells 58
Targeting Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Agonistic Receptors for Cancer Therapy 58
Arachidonic acid mediates interleukin-1 and tumor necrosis factor-alpha-induced activation sf the c-jun amino-terminal kinases in stromal cells 58
High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors : mature results of an Italian randomized phase II study 58
The parallel between CD45 expression and extra-medullary evolution in aggressive myeloma with high serum lactate dehydrogenase 58
Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts 58
Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation : results from a named patient program at four Italian centers 58
Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed 58
In vitro growth of mobilized peripheral blood progenitor cells is significantly enhanced by stem cell factor 57
INTERFERONS AS BIOLOGIC MODULATORS OF HEMATOPOIETIC-CELL PROLIFERATION AND DIFFERENTIATION 57
Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients 57
Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies : posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery 57
Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma 57
Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF 57
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma 57
Totale 7.084
Salva come PNG Salva come JPEG
Categoria #
all - tutte 123.083
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 123.083
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.222 0 0 0 0 0 751 336 147 445 303 8 232
2021/20221.277 68 5 19 275 19 20 30 165 130 193 286 67
2022/20233.390 487 102 293 411 326 292 0 310 604 281 236 48
2023/20241.820 139 218 335 41 30 128 67 132 24 36 280 390
2024/20253.375 88 65 33 69 85 328 197 404 531 802 403 370
2025/20263.400 1.247 462 642 743 233 73 0 0 0 0 0 0
Totale 15.527